Vasodilators in Heart Failure: Conclusions from V-HeFT II and Rationale for V-HeFT III

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The Veterans Affairs Vasodilator-Heart Failure Trials (V-HeFT I and II) provided information about heart failure treated with conventional therapy, and evaluated the long term efficacy of vasodilators. In V-HeFT I, the combination of hydralazine and isosorbide dinitrate provided a beneficial effect on prognosis in heart failure. V-HeFT II demonstrated that enalapril had a more favourable effect on 2-year survival than a combination of hydralazine plus isosorbide dinitrate. However, the hydralazine-isosorbide dinitrate combination exerted the most favourable short term impact on exercise performance and left ventricular ejection fraction. The V-HeFT studies showed that, although not all vasodilators are alike, their differing effects might be beneficial when used in combination. Determination of the potential additive effect of the calcium antagonist felodipine, a vasodilator, when used in combination with an ACE inhibitor, is the major goal of V-HeFT III.

Original languageEnglish (US)
Pages (from-to)47-58
Number of pages12
JournalDrugs
Volume47
Issue number4
DOIs
StatePublished - Jan 1 1994

Fingerprint

Vasodilator Agents
Heart Failure
Felodipine
Enalapril
Veterans
Angiotensin-Converting Enzyme Inhibitors
Stroke Volume
Exercise
Calcium
Survival
isosorbide-hydralazine combination
Therapeutics

Cite this

Vasodilators in Heart Failure : Conclusions from V-HeFT II and Rationale for V-HeFT III. / Cohn, Jay N.

In: Drugs, Vol. 47, No. 4, 01.01.1994, p. 47-58.

Research output: Contribution to journalArticle

@article{69a98cdf730f44a1a1af7473015c1a8e,
title = "Vasodilators in Heart Failure: Conclusions from V-HeFT II and Rationale for V-HeFT III",
abstract = "The Veterans Affairs Vasodilator-Heart Failure Trials (V-HeFT I and II) provided information about heart failure treated with conventional therapy, and evaluated the long term efficacy of vasodilators. In V-HeFT I, the combination of hydralazine and isosorbide dinitrate provided a beneficial effect on prognosis in heart failure. V-HeFT II demonstrated that enalapril had a more favourable effect on 2-year survival than a combination of hydralazine plus isosorbide dinitrate. However, the hydralazine-isosorbide dinitrate combination exerted the most favourable short term impact on exercise performance and left ventricular ejection fraction. The V-HeFT studies showed that, although not all vasodilators are alike, their differing effects might be beneficial when used in combination. Determination of the potential additive effect of the calcium antagonist felodipine, a vasodilator, when used in combination with an ACE inhibitor, is the major goal of V-HeFT III.",
author = "Cohn, {Jay N}",
year = "1994",
month = "1",
day = "1",
doi = "10.2165/00003495-199400474-00008",
language = "English (US)",
volume = "47",
pages = "47--58",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Vasodilators in Heart Failure

T2 - Conclusions from V-HeFT II and Rationale for V-HeFT III

AU - Cohn, Jay N

PY - 1994/1/1

Y1 - 1994/1/1

N2 - The Veterans Affairs Vasodilator-Heart Failure Trials (V-HeFT I and II) provided information about heart failure treated with conventional therapy, and evaluated the long term efficacy of vasodilators. In V-HeFT I, the combination of hydralazine and isosorbide dinitrate provided a beneficial effect on prognosis in heart failure. V-HeFT II demonstrated that enalapril had a more favourable effect on 2-year survival than a combination of hydralazine plus isosorbide dinitrate. However, the hydralazine-isosorbide dinitrate combination exerted the most favourable short term impact on exercise performance and left ventricular ejection fraction. The V-HeFT studies showed that, although not all vasodilators are alike, their differing effects might be beneficial when used in combination. Determination of the potential additive effect of the calcium antagonist felodipine, a vasodilator, when used in combination with an ACE inhibitor, is the major goal of V-HeFT III.

AB - The Veterans Affairs Vasodilator-Heart Failure Trials (V-HeFT I and II) provided information about heart failure treated with conventional therapy, and evaluated the long term efficacy of vasodilators. In V-HeFT I, the combination of hydralazine and isosorbide dinitrate provided a beneficial effect on prognosis in heart failure. V-HeFT II demonstrated that enalapril had a more favourable effect on 2-year survival than a combination of hydralazine plus isosorbide dinitrate. However, the hydralazine-isosorbide dinitrate combination exerted the most favourable short term impact on exercise performance and left ventricular ejection fraction. The V-HeFT studies showed that, although not all vasodilators are alike, their differing effects might be beneficial when used in combination. Determination of the potential additive effect of the calcium antagonist felodipine, a vasodilator, when used in combination with an ACE inhibitor, is the major goal of V-HeFT III.

UR - http://www.scopus.com/inward/record.url?scp=0028217598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028217598&partnerID=8YFLogxK

U2 - 10.2165/00003495-199400474-00008

DO - 10.2165/00003495-199400474-00008

M3 - Article

C2 - 7523062

AN - SCOPUS:0028217598

VL - 47

SP - 47

EP - 58

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 4

ER -